Impact of quetiapine prolong and escitalopram on the hypothalamic-pituitary-adrenocortical (HPA)-axis activity in depressed patients
- Conditions
- In this study, patients suffering from unipolar depression are investigated. 40 unipolar depressed inpatients (age 18-65) enter the study after the procedure has been fully explained and written informed consent has been obtained. The patients are diagnosed by experienced and trained psychiatrists according to DSM-IV criteria (296.2, 296.3) using the Structured Clinical Interview for DSM-IV, German version (Wittchen et al. 1997).MedDRA version: 9.1Level: LLTClassification code 10012378Term: Depression
- Registration Number
- EUCTR2009-011911-19-DE
- Lead Sponsor
- udwig-Maximilian-University of Munich, Department of Psychiatry
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- Not specified
1.Inpatients (the admission to hospital occurs independently from study participation)
2.Provision of written informed consent
3.A diagnosis of major depression by Diagnostic and Statistical Manual of Mental Disorders- Fourth Edition (DSM-IV) (unipolar depression: 296.2, 296.3)
4.Female and male patients aged 18 to 65 years
5.Female patients of childbearing potential must have a negative serum human chorionic gonadotropin (hCG) pregnancy test at enrolment and e willing to use a reliable method of birth control (i.e. barrier method, oral contraceptive, implant, dermal contraception, long-term injectable contraceptive, intrauterine device, or tubal litigation) during the study.
6.Able to understand and comply with the requirements of the study as judged by the investigator.
7.A sum score of at least 18 on the 21-item version of the Hamilton Depression Rating Scale (21-HAMD)
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
1.Pregnancy or lactation
2.Any DSM-IV Axis I disorder not defined in the inclusion criteria
3.Patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to self or others
4.Known intolerance or lack of response to quetiapine fumarate and/or escitalopram, as judged by the investigator
5.Use of any of the following cytochrome P450 3A4 inhibitors in the 14 days preceding enrolment including but not limited to: ketoconazole, itraconazole, fluconazole, erythromycin, clarithromycin, troleandomycin, indinavir, nelfinavir, ritonavir, fluvoxamine and saquinavir
6.Use of any of the following cytochrome P450 3A4 inducers in the 14 days preceding enrolment including but not limited to: phenytoin, carbamazepine, barbiturates, rifampin, St. John’s Wort, and glucocorticoids
7.Use of monoamine oxidase inhibitors (MAOIs) or other serotonergic drugs (e.g. triptanes) in the 14 days preceding enrolment
8.Use of oral anticoagulants in the 14 days preceding enrolment
9.History of bleeding disorders.
10.Use of drugs which are mainly metabolized by cytochrome P450 2D6 having a low therapeutic index (e.g. flecainide, propafenone, metoprolole) in the 14 days preceding enrolment
11.Administration of a depot antipsychotic injection within one dosing interval (for the depot) before randomisation
12.Substance or alcohol dependence at enrolment (except dependence in full remission, and except for caffeine or nicotine dependence), as defined by DSM-IV criteria
13.Opiates, amphetamine, barbiturate, cocaine, cannabis, or hallucinogen abuse by DSM-IV criteria within 4 weeks prior to enrolment
14.Medical conditions that would affect absorption, distribution, metabolism, or excretion of study treatment
15.Unstable or inadequately treated medical illness (e.g. congestive heart failure, angina pectoris, hypertension) as judged by the investigator
16.Involvement in the planning and conduct of the study
17.Previous enrolment or randomisation of treatment in the present study.
18.Participation in another drug trial within 4 weeks prior enrolment into this study or longer in accordance with local requirements
19.A patient with Diabetes Mellitus (DM) fulfilling one of the following criteria:
•Unstable DM defined as enrolment glycosylated hemoglobin (HbA1c) >8.5%.
•Admitted to hospital for treatment of DM or DM related illness in past 12 weeks.
•Not under physician care for DM
•Physician responsible for patient’s DM care has not indicated that patient’s DM is controlled.
•Physician responsible for patient’s DM care has not approved patient’s participation in the study
•Has not been on the same dose of oral hypoglycaemic drug(s) and/or diet for the 4 weeks prior to randomisation. For thiazolidinediones (glitazones) this period should not be less than 8 Weeks.
•Taking insulin whose daily dose on one occasion in the past 4 weeks has been more than 10% above or below their mean dose in the preceding 4 weeks
Note: If a diabetic patient meets one of these criteria, the patient is to be excluded even if the treating physician believes that the patient is stable and can participate in the study.
20.An absolute neutrophil count (ANC) of <= 1.5 x 10exp9 per liter
21.Abnormal laboratory parameters of clinical relevance before enrolment
22.Abnormal blood pressure, abnormal electrocardiogram, and/or abnormal electroencephalogram with clinical relevance before enrolment
23.Psychotropic drugs within 3 days before and throug
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method